Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 6/20 | 0.73 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 5/20 | 0.58 |
| ▸ | ABL1 | P00519 | 4/20 | 0.58 |
| ▸ | RET | P07949 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
| ▸ | YES1 | P07947 | 2/20 | 0.46 |
| ▸ | LYN | P07948 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063431 | 0.94 | VCP (0.68) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL5063574 | 0.94 | VCP (0.68) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL3785337 | 0.93 | VCP (0.64) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL13019748 | 0.88 | HTT (0.65) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL5064857 | 0.87 | VCP (0.68) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL13673068 | 0.85 | VCP (0.82) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL13020230 | 0.85 | VCP (0.53) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL13669446 | 0.84 | VCP (1.00) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL13669424 | 0.84 | VCP (1.00) | VCPPSMC4HTTKDM4EALDH1A1 | |
| SCHEMBL13019743 | 0.83 | HTT (0.59) | VCPPSMC4HTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213900-A1 | Engineered Protein Kinases Which Can Utilize Modified Nucleotide Triphosphate Substrates | SHOKAT KEVAN | 2008-09-04 | — | — | US | disclosed |
| US-20060263800-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY | 2006-11-23 | — | — | US | disclosed |
| US-7049116-B2 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY (US) | 2006-05-23 | — | — | US | disclosed |
| US-7026461-B1 | Radiolabeled nucleotide triphosphate compound where at least on phosphorus atom is radioactive that serves as a substrate for a mutant form of a wild-type kinase but not the wild-type form; kits; use of subtrate in assays to determine if test compounds can modulate said mutant enzyme | PRINCETON UNIVERSITY (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1607481-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1017823-B1 | ENGINEERED PROTEIN KINASES WHICH CAN UTILIZE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES | UNIV PRINCETON (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1140938-B1 | HIGH AFFINITY INHIBITORS FOR TARGET VALIDATION AND USES THEREOF | UNIV PRINCETON (US) | 2003-08-27 | — | — | EP | disclosed |
| EP-1321467-A2 | High affinity inhibitors for target validation and uses thereof | Princeton University (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | PRINCETON UNIVERSITY | 2003-04-17 | — | — | US | disclosed |
| US-6521417-B1 | Incubating permeabilized cells expressing mutant kinase with radiolabeled analog; cytolysis, separation by sodium dodecyl sulfate polyacrylamide gel electrophoresis | PRINCETON UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| US-20020146797-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY. | 2002-10-10 | — | — | US | disclosed |
| US-6390821-B1 | PHOSPHORYLATION | PRINCETON UNIVERSITY | 2002-05-21 | — | — | US | disclosed |
| US-6383790-B1 | PYRAZOLO(3,4-D)PYRIMIDINE BASED COMPOUND; ANTICARCINOGENIC AGENTS; ANTITUMOR AGENTS | PRINCETON UNIVERSITY | 2002-05-07 | — | — | US | disclosed |
| US-20020016976-A1 | Engineered protein kinases which can utilize modified nucleotide triphosphate substrates | PRINCETON UNIVERSITY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073218-A1 | High affinity inhibitors for target validation and uses thereof | SRC, MARCKS, TEC | VCP 710/4885PSMC4 3179/4885HTT 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.